The FDA established the platform to allow scientists to test their NGS assays and to advance the regulatory science for assessing genomic tests and software.
Using funds from the California precision medicine initiative, the group will use its bioinformatics expertise to match patients to treatments in pediatric clinical trials.
The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.
The so-called HgV platform offers tools for analyzing high-throughput whole genome sequence data for precision medicine research and clinical applications
